Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Clinical impact of epoetins in the treatment of anemia with special emphasis on patients with lymphoid malignancies.: dosing, iron supplementation and safety
Umeå universitet, Medicinsk fakultet, Strålningsvetenskaper.
2007 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with lymphoproliferative diseases (LPD) and chemotherapy induced anemia (CIA), to study the clinical impact of intravenous (IV) iron supplementation combined with epoetin beta treatment, to identify factors that might predict hemoglobin (Hb) response to treatment with epoetins and to investigate safety of DA.

A dose-finding phase II study was able to assess a reasonable DA dose of 2.25 μg/kg once weekly for the treatment of CIA in patients with LPD. Dose-response trends were observed for the different dose cohorts although not statistically significant for any of the endpoints. However a significantly higher proportion of patients achieved Hb response (increase ≥2 g/dL) in the combined DA groups than in placebo (P<0.001).

A larger pivotal phase II trial was performed in a similar setting o confirm that the dose 2.25μg/kg once weekly was appropriate and safe. The proportion of patients achieving Hb response was significantly higher in the DA group (60%) than in the placebo group (18%) (P<0,001) and resulted in higher mean changes in Hb than placebo from baseline, 2.66 g/dl versus 0.69 /dl. Also a significantly lower proportion of patients in the DA group (31%) received RBC tranfusions than in the placebo group (48%). The short-term safety of DA with the tested dose was confirmed. The efficacy of DA was consistent for all end points independent of malignancy type or baseline endogenous erythropoietin serum levels.

The correction of moderate anemia in truly iron repleted patients with clinically stable LPD not receiving hemotherapy or RBC transfusions with epoetin beta treatment, with or without IV iron treatment was studied in an open label randomized trial. Also the impact on iron kinetics was assessed. The mean change in Hb concentration from baseline to end of treatment (EOT ) was 2.91 versus 1.50 g/dL respectively (P<0.0001). There was a significant (P<0.0001) difference in mean Hb at EOT between the iron and no-iron groups (13.0 g/dL versus 11.8 g/dL). Hb response was achieved by significantly more patients in the iron group (P=0.0012)than in the no-iron group (93% versus 53%) and the median time to achieve a Hb response was 6 weeks in the iron group compared with 12 weeks in the no-iron group. The mean weekly epoetin dose per patient was statistically significant lower in the iron group at week 13 (P =0.029) and at least 25% lower at EOT.

To investigate the long-term safety of DA in cancer patients with CIA four previously published double blind, randomized placebo-controlled phase II -III studies were analysed (n = 1.129). Median durations of progression-free survival and overall survival was comparable between DA and placebo for lung cancer (median follow up 15.8 months), for LPD (median follow up 32.6 months) and in the pooled population (follow up 4 months).

sted, utgiver, år, opplag, sider
Umeå: Strålningsvetenskaper , 2007. , s. 58
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1069
Emneord [en]
anemia, cancer, lymphoproliferative malignancies, erythropoietin, intravenous iron, safety
HSV kategori
Forskningsprogram
onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-1024ISBN: 91-7264-214-9 (tryckt)OAI: oai:DiVA.org:umu-1024DiVA, id: diva2:139995
Disputas
2007-03-16, 244, Lionssalen, 7, Norrlands universitetssjukhus, Umeå, 13:00 (engelsk)
Opponent
Veileder
Tilgjengelig fra: 2007-02-22 Laget: 2007-02-22 Sist oppdatert: 2009-05-19bibliografisk kontrollert
Delarbeid
1. Randomized dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
Åpne denne publikasjonen i ny fane eller vindu >>Randomized dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
Vise andre…
2002 (engelsk)Inngår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 119, nr 1, s. 79-86Artikkel i tidsskrift (Fagfellevurdert) Published
Identifikatorer
urn:nbn:se:umu:diva-2146 (URN)
Tilgjengelig fra: 2007-02-22 Laget: 2007-02-22 Sist oppdatert: 2017-12-14bibliografisk kontrollert
2. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study
Åpne denne publikasjonen i ny fane eller vindu >>Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study
Vise andre…
2003 (engelsk)Inngår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 122, nr 3, s. 394-403Artikkel i tidsskrift (Fagfellevurdert) Published
Identifikatorer
urn:nbn:se:umu:diva-2147 (URN)
Tilgjengelig fra: 2007-02-22 Laget: 2007-02-22 Sist oppdatert: 2017-12-14bibliografisk kontrollert
3. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study.
Åpne denne publikasjonen i ny fane eller vindu >>Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study.
Vise andre…
2007 (engelsk)Inngår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 21, nr 4, s. 627-632Artikkel i tidsskrift (Fagfellevurdert) Published
Emneord
anemia, cancer, erythropoietin, intravenous iron, lymphoproliferative malignancies
Identifikatorer
urn:nbn:se:umu:diva-12258 (URN)doi:10.1038/sj.leu.2404562 (DOI)17252006 (PubMedID)
Tilgjengelig fra: 2007-03-28 Laget: 2007-03-28 Sist oppdatert: 2017-12-14bibliografisk kontrollert
4. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
Åpne denne publikasjonen i ny fane eller vindu >>Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
Vise andre…
2005 (engelsk)Inngår i: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 23, nr 28, s. 6941-6948Artikkel i tidsskrift (Fagfellevurdert) Published
Identifikatorer
urn:nbn:se:umu:diva-14364 (URN)doi:10.1200/jco.2005.03.434 (DOI)16192582 (PubMedID)
Tilgjengelig fra: 2006-11-09 Laget: 2006-11-09 Sist oppdatert: 2017-12-14bibliografisk kontrollert

Open Access i DiVA

fulltekst(1019 kB)1501 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1019 kBChecksum SHA-1
ae3dfa4138e3f0b9b80f19af5f752d7559e50f5410f5b637febba628b5aee0a390fed985
Type fulltextMimetype application/pdf

Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 1504 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

isbn
urn-nbn

Altmetric

isbn
urn-nbn
Totalt: 1279 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf